Skip to content | Change text size
 

Professor Susan A Charman

Photo of Associate Professor Susan Charman, Pharmaceutics

Professor of Pharmaceutics
Director, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

BS Florida State University (USA)
PhD University of Florida (USA)

Telephone: +61 3 9903 9626
Fax: +61 3 9903 9627
Email: susan.charman@monash.edu

Theme Leader, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

Research interests

  • The development, establishment and application of lead optimisation technologies to rapidly identify, design and select the best drug discovery candidates for further pre-clinical and clinical development
  • The specific application of lead optimisation strategies to discover and develop new drugs for neglected diseases (in particular malaria) and cancer

Representative publications

  1. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FCK, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. PNAS. 2011; 108:4400-4405.
  2. Dong YD, Wittlin S, Sriraghavan K, Chollet J, Charman SA, et al. The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). Journal od Medicinal Chemistry. 2010; 53:481-491.  
  3. Bhamidipati RK, Morizzi J, Chiu FCK, Shackleford DM, Vennerstrom JL, Charman SA. Simultaneous determintaion of OZ277, a synthetic 1,2,4-trioxoloane antimalarial, and its polr metabolites employing hydrophilic interaction chromatography. Journal of Chromatohraphy B. 2009. 877:2989-2995.
  4. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, Vennerstrom JL, Charman SA. Stability of peroxide antimalarials in the presence of human hemoglobin. Antimicrobial Agents and Chemotherapy. 2009; 53: 3496-3500.
  5. Gujjar R, Marwaha A, El MAzouni F, White J, White KL, Creason S, Shackleford D, Baldwin J, Charman WN, Buckner FS, Charman SA, Rathod PK, Phillips MA. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. Journal of Medicinal Chemistry. 2009; 52(7):1864-1872
  6. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Huggins P, Parsons J, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li Q, Charman SA, et.al.  Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Aβ. Neuron. 2008; 59:43-55.
  7. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, Vennerstrom JL, Charman SA, et.al. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. Antimicrobial Agents and Chemotherapy. 2008;52(4):1291-1296.
  8. Kota J, Machavaram K, McLennan D, Edwards G, Porter CJH, Charman SA. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepetin alfa using a sheep model. Drug Metabolism and Disposition. 2007;35(12):2211-2217
  9. Wang X, Dong YD, Wittlin S, Creek DJ, Chollet J, Charman SA, Vennerstrom JL. Spiro and dispiro-1,2-dioxolanes: contribution of iron(II)-mediated one-electron vs. two-electron reduction to the activity of antimalarial peroxides. Journal of Medicinal Chemistry. 2007;50:5840-5847.
  10. Creek DJ, Charman WN, Chiu FCK, Prankerd R, McCullough KJ, Charman SA, et.al.  Iron-Mediated Degredation Kinetics of Substituted Dispiro-1,2,4-trioxolane Antimalarials. Journal of Pharmaceutical Sciences. 2007;96(11), 2945-2956.
  11. Dong YD, Creek DJ, Chollet J, Matile H, Charman SA, Wittlin S, Wood JK, Vennerstrom JL, Charman SA.  Iron-mediated degredation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials. Joutrnal of Pharmaceutical Science. 2007; 96:2945-2956.
  12. Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. Journal of Antimicrobial Chemotherapy. 2006. 58:52-58.
  13. Charman SA, Perry CS, Chiu FCK, McIntosh KA, Prankerd RJ, Charman WN. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalrial in the presence of a modified cyclodextrin. Journal of Pharmaceutical Science. 2006; 95:256-267.
  14. Dong YD, Chollet J, Matile H, Charman SA, Chiu F, Charman WN, et.al. Spiro and Dispiro-1,2,4-Trioxolanes as Antimalarial Peroxides: Charting a Workable Structure - Activity Relationship Using Simple Prototypes. Journal of Medicinal Chemistry. 2005; 48:4953-4961.
  15. Creek DJ, Chiu F, Prankerd R, Charman SA, Charman WN. Kinetics of Iron-Mediated Artemisinin Degradation: Effect of Solvent Composition and Iron Salt. Journal of Pharmaceutical Sciences. 2005;94:1820-1829.Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004;430:900-904.
  16. McLennan DN, Porter CJH, Edwards GA, Martin SW, Heatherington AC, Charman SA.  Lymphatic absorption is the primary contributor to the systemic availability of epotein alfa following subcutaneous administration to sheep.  Journal of Pharmacology and Experimental Therapies. 2005; 313:345-351.
  17. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, et.al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004; 430:900-904.
  18. Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration. Journal of Pharmaceutical Science. 2000. 89:297-310.
  19. Charman SA, Mason KL, Charman WN. Techniques for assessing the effects of pharmaceutical excipients of the aggregation of porcine growth hormone. Pharmaceutical Research. 1993; 7:954-962.
  20. Charman SA, Charman WN, Wilson TD, Rogge MC, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharmaceutical Research. 1992; 9:87-93.

External appointments

  • Member of the Pharmaceutical Industry Working Group, Australia
  • Member of the Expert Discovery Advisory Committee, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland
  • Member of the Scientific Advisory Board, Consortium of Parasitic Drug Development (CPDD), University of North Carolina, USA
  • Member of the Management Committee, Biopharmaceutical Formulation Centre, Melbourne, Austraila
  • Member of the International Affairs Committee, American Association of  Pharmaceutical Scientists